Thermo Fisher Scientific Inc. has introduced the Gibco CTS OpTmizer One Serum-Free Medium (CTS OpTmizer One SFM), a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion. As a result, cell therapy manufacturers can use CTS OpTmizer One SFmizer One SFM to help optimize their workflows and get T cell therapies to patients faster. CTSOpTmizer One SFM's ready-to-use, one-part medium can help cell therapy manufacturers scale their manufacturing from process development to clinical trials and commercial manufacturing while maintaining consistent performance.

As part of the cell expansion process, CTS OpTmizer one SFM delivers high cellviability, improved growth and maintains early memory T cell phenotype. In addition, the AOF formulation can help in mitigating risk by reducing opportunities for contamination or inconsistency due to animal- origin (AO) components. The ability to more-rapidly expand less-differentiated T cells to reach a desired dose can help manufacturers shorten the time to treatment, lower manufacturing costs, increase patient access, and enhance therapeutic efficacy.

OpTmizer OneSFM's ready-to- use, one-part medium advances T cell expansion and cell growth while helping cell therapy manufacturers improve overall drug function for both autologous and allogeneic therapies, when compared to other leading AOF T cell media. Workflows featuring CTS OpTmizerOne SFM display a high level of consistency across small and large scales and various culture vessels, such as G-Rex?? plates, rocking motion bioreactors and stirred tank bioreactors.

This flexibility allows CTS OpTmizer 1 SFM to be leveraged in both autologous and allogenic workflows. Available as a catalog product in 1 L bottles and 1 L, 5 L, and 10 L bioprocess containers, CTS OpTmizers One SFM is compatible with closed automated instruments such as the Gibco?? C TS??

DynaCellect?? Magnetic Separation System and the Gibco?? Rotea Counterflow Centrifugation System.

The CTS OpTmizerone SFM expands Thermo Fisher Scientific's Gibco Cell Therapy Systems (CTS) portfolio of products. Individually and as a platform, the Gibco CTS portfolio deliver flexibility, efficiency, productivity and scalability across the cell therapy manufacturing workflow. The Gibco CTS portfolio of cell and gene therapy products are GMP manufactured, safety tested and backed by regulatory documentation to help customers transition from discovery through clinical and commercial manufacturing.